High-dose melphalan with autologous stem cell transplantation (auto-SCT) has significantly improved survival of MM patients [1] [2] [3] , however the majority of patients eventually experience relapse. Among strategies to improve outcomes after auto-SCT is the use of maintenance therapy to sustain disease response and delay relapse.
Thalidomide was the first novel agent evaluated as maintenance therapy. Although posttransplant thalidomide improves progression-free survival (PFS) and overall survival (OS) 4 , prolonged use is limited by peripheral neuropathy, the main cause of treatment discontinuation 5 . Lenalidomide, a more potent and less toxic second-generation immunomodulatory drug (IMiD), is currently the only agent approved for post-transplant maintenance, based on improved PFS with lenalidomide versus placebo or observation [6] [7] [8] [9] .
Moreover, lenalidomide maintenance also prolongs OS with a reduced risk of death by approximately 25% 9, 10 . Prolonged use of lenalidomide, however, is associated with increased risk of cytopenias, diarrhea, thromboembolic events, and secondary primary malignancies (SPMs) 10 . Furthermore, the efficacy in patients with high-risk cytogenetics remains a matter of debate with a meta-analysis showing no survival benefit in this patient subset 10 . In contrast, the Myeloma XI study showed improved OS irrespective of cytogenetic risk, but lenalidomide maintenance did not completely abrogate the inferior outcomes associated with adverse cytogenetic abnormalities 9 .
Importantly, the use of the proteasome inhibitor, bortezomib, for induction and as posttransplant maintenance improves outcomes of newly diagnosed MM patients, especially those with high-risk features such as del(17p) 11 . Long-term bortezomib therapy, however, is limited by neurotoxicity, and the inconvenience of subcutaneous administration. Thus, the development of the oral proteasome inhibitor, ixazomib, represents an important advance.
In The Lancet, Meletios Dimopoulos and colleagues report the results of a randomized phase 3 study (TOURMALINE-MM3), in which newly diagnosed MM patients, treated with standard-of-care induction therapy followed by high-dose melphalan and auto-SCT, were randomly assigned to receive once-weekly ixazomib or placebo for 3 weeks out of a 4 week cycle for 26 cycles or until progression. Ixazomib maintenance improved depth of response, when compared to the placebo group. At a median follow-up of 31 months, median PFS in patients receiving ixazomib was 26.5 months, compared to 21.3 months in the placebo group, representing a 28% reduction in risk of death or progression. The PFS benefit of ixazomib maintenance was observed irrespective of cytogenetic risk or MRD status at study entry. Importantly, ixazomib maintenance was well tolerated with low rates of polyneuropathy, and without increased risk of thromboembolic events or SPMs. Although, thrombocytopenia and gastrointestinal adverse events were more common with ixazomib, these were largely grade 1/2. This translated into a similar rate of treatment discontinuation and equivalent quality of life in the ixazomib and placebo groups.
Several questions, however, remain to be answered. Although direct comparisons of postauto-SCT maintenance studies are confounded by differences in patient populations and induction regimens, PFS benefit was more modest with ixazomib maintenance, when compared to studies with lenalidomide (median PFS in meta-analysis: 52.8 months in lenalidomide group versus 23.5 months in control group 10 ) . This difference in activity may be related to variability in treatment duration (fixed duration versus treatment until progression), or suboptimal ixazomib dose intensity. In addition, there are important biological differences between agents, and the immune stimulating effects of lenalidomide may contribute to long-term control of residual MM cells.
It is currently also unknown whether ixazomib maintenance leads to the development of drug-resistant relapses, or affects response to subsequent proteasome inhibitor-based treatment. Analysis of PFS2 and OS is important in this context, but this requires longer follow-up. Furthermore, in the absence of a head-to-head comparison between ixazomib and lenalidomide, it is currently unclear which specific subgroups may benefit from ixazomib maintenance. Ixazomib may be a new maintenance option for patients intolerant to lenalidomide, or those with high-risk disease. The good tolerability profile of ixazomib (discontinuation due to adverse events: 7% versus 29% with lenalidomide 10 ), may also facilitate combinations with other anti-MM agents, for example, ongoing trials are evaluating ixazomib plus lenalidomide maintenance, which may be of particular value in high-risk disease 12 . In the future, MRD-assessments may help to identify patients for more intensive maintenance strategies, and also guide optimal treatment duration to reduce adverse events and financial toxicity. Altogether, it is expected that such new maintenance strategies will further improve outcomes in MM, and the development of ixazomib as a maintenance agent is an important step in this direction.
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